All In Biotech

Drug Trial Radar · NCT05705505

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination With Letrozole as Therapy for the Treatment of Recurrent Metastatic Endometrial Cancer and Other Gynecologic Malignancies

Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 29, 2023

Primary completion

Jan 2026

Study completion Feb 2026

Sponsor

Lead sponsor
Traws Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of increasing doses of narazaciclib (ON 123300) in combination with the standard daily dose (2.5mg) of letrozole in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer and other Gynecologic Malignancies.

Conditions

  • Endometrioid Endometrial Cancer

Interventions

  • NarazaciclibDrug

    Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate

  • Letrozole 2.5mgDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs) will be tabulated and summarized by cohortTime frame: From First dose until end of Cycle 1 (28 days)
  2. Treatment-emergent adverse events (TEAEs), including DLTs will be graded by CTCAE v5.0Time frame: From first dose until 30 days after final dose, up to approximately 1 year
  3. Phase 2 - Progression-free survival (PFS) at 24 weeks by Investigator assessmentTime frame: Measured from first dose until 24-weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC - HOPE

    Tucson, Arizona · Recruiting

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota · Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • NYU Langone

    New York, New York · Recruiting

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon · Recruiting

  • Greenville Health System, Institute for Oncology Clinical Research

    Greenville, South Carolina · Recruiting

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Recruiting

  • Texas Oncology - Fort Worth Cancer Center

    Fort Worth, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.